The High-Throughput Drug Screening Core Facility (HTSCF) helps investigators discover and develop new chemical probes, identify novel genes or gene functions, and study biological processes.
Established in 2003, the facility seeks to facilitate research in chemical biology and functional genomics at Memorial Sloan-Kettering. We also offer screening services to investigators at other institutions.
The HTSCF is a fee-for-service facility dedicated to providing the following services:
In RNAi screening, gene silencing by RNA interference technology is used to identify genes involved in a specific cellular pathway. We perform arrayed, genome-wide RNAi screening using both siRNA duplex– and shRNA hairpin–based technologies.
We have developed an analysis strategy through a stringent, five-step process called the Bhinder-Djaballah (BDA) analysis method. It involves the introduction of the H score as a measure of combined duplex activities toward hit nomination with a minimum score of 60.
In addition, we address off-target effects (OTEs) by performing a comprehensive analysis to eliminate duplexes from the analysis, or by flagging the activities of such duplexes as potential OTEs based on their seed sequence similarities to miRNAs or 3’UTR sequences.
When applied to random RNAi data, the BDA method filters out inherent noise due to the heterogeneous nature of RNAi screening and cell biology.
RNAi Screening Libraries
Below are the different types of libraries we provide for RNAi screening:
All our RNAi screening libraries are arrayed in 384-well microtiter plates.
High-Throughput Drug Screening Facility has not received any reviews.
High-Throughput Drug Screening Facility has not received any endorsements.